| CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia (NCT07657780) | CorrectSequence Therapeutics Co., Ltd | 2026-06-15 |
| A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major (NCT07489196) | CorrectSequence Therapeutics Co., Ltd | 2026-04-05 |
| CS-121 APOC3 Base Editing in FCS (NCT07176923) | CorrectSequence Therapeutics Co., Ltd | 2025-10-15 |
| A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection (NCT06717932) | CorrectSequence Therapeutics Co., Ltd | 2025-05-15 |
| A Long-term Follow-up Study in Participants Who Received CS-101 (NCT06685536) | CorrectSequence Therapeutics Co., Ltd | 2025-01-18 |
| CS-206 in Patients With Sickle Cell Disease (NCT06565026) | CorrectSequence Therapeutics Co., Ltd | 2024-09-02 |
| A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major (NCT06291961) | CorrectSequence Therapeutics Co., Ltd | 2024-04-18 |
| CS-101 in Patients With β-thalassemia (NCT06328764) | CorrectSequence Therapeutics Co., Ltd | 2024-03-19 |
| A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia (NCT06024876) | CorrectSequence Therapeutics Co., Ltd | 2023-08-26 |